ALNY

Alnylam Pharmaceuticals Inc

Jul 16 • 12:46PM ET

319.04

Dollar change +7.92
Percentage change 2.55	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO VXF VUG VOT IWP IBB CGGR IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.09	Insider Own	4.37%	Shs Outstand	130.31M	Perf Week	-0.57%
Market Cap	41.60B	Forward P/E	137.02	EPS next Y	2.33	Insider Trans	-2.85%	Shs Float	124.69M	Perf Month	3.59%
Enterprise Value	41.69B	PEG	-	EPS next Q	-0.59	Inst Own	96.23%	Short Float	2.67%	Perf Quarter	32.93%
Income	-269.70M	P/S	17.72	EPS this Y	67.52%	Inst Trans	1.68%	Short Ratio	3.59	Perf Half Y	23.53%
Sales	2.35B	P/B	360.16	EPS next Y	428.87%	ROA	-6.71%	Short Interest	3.33M	Perf YTD	35.58%
Book/sh	0.89	P/C	15.80	EPS next 5Y	-	ROE	-	52W High	333.70 -4.39%	Perf Year	22.47%
Cash/sh	20.19	P/FCF	-	EPS past 3/5Y	32.86% 23.11%	ROIC	-9.95%	52W Low	205.87 54.97%	Perf 3Y	109.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.61% 59.21%	Gross Margin	86.01%	Volatility	2.27% 2.71%	Perf 5Y	98.88%
Dividend TTM	-	EV/Sales	17.75	EPS Y/Y TTM	21.16%	Oper. Margin	-4.91%	ATR (14)	9.01	Perf 10Y	166.91%
Dividend Ex-Date	-	Quick Ratio	2.98	Sales Y/Y TTM	17.21%	Profit Margin	-11.49%	RSI (14)	54.76	Recom	1.79
Dividend Gr. 3/5Y	- -	Current Ratio	3.04	EPS Q/Q	15.21%	SMA20	-0.11%	Beta	0.24	Target Price	337.93
Payout	-	Debt/Eq	23.58	Sales Q/Q	20.20%	SMA50	5.86%	Rel Volume	0.88	Prev Close	311.12
Employees	2230	LT Debt/Eq	22.47	Earnings	May 01 BMO	SMA200	18.69%	Avg Volume	926.77K	Price	319.04
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.56% 1.55%	Trades		Volume	432,083	Change	2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178

Show Previous Ratings

Jul-02-25 12:30PM	OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients (PR Newswire)
Jun-29-25 09:50PM	BMO Capital Maintains 'Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT (Insider Monkey)
Jun-19-25 10:10AM	Alnylam names Pushkal Garg as EVP, chief research and development officer (TipRanks)
Jun-18-25 10:05AM	Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer (Business Wire)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
07:31PM	Loading…
Jun-11-25 07:31PM	The European Commission Approves Alnylam's AMVUTTRA (Insider Monkey)
07:00AM	Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
05:21AM	EC approves Alnylams vutrisiran for ATTR-CM treatment (Pharmaceutical Technology)
Jun-09-25 06:00AM	Alnylam Receives European Commission Approval for AMVUTTRA (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Jun-05-25 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report? (Zacks)
06:20AM	Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar? (Zacks)
May-28-25 08:00AM	Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference (Business Wire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-20-25 09:00AM	Alnylam Issues 2024 Corporate Responsibility Report (Business Wire)
07:25PM	Loading…
May-19-25 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
May-17-25 05:50AM	AMVUTTRA (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B (Business Wire)
May-13-25 10:18PM	Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-12-25 07:00AM	Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress (Business Wire) +7.58%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -6.58%
04:00AM	Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications (Pharma Voice)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 07:17PM	Tracking Baillie Gifford's 13F Portfolio - Q1 2025 Update (Seeking Alpha)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
May-05-25 10:00AM	Fidelity OTC Portfolio Q1 2025 Commentary (Seeking Alpha) +5.46%
10:00AM	Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference (Business Wire)
May-02-25 10:51AM	Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y (Zacks)
03:05AM	Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:29AM	Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
10:46PM	Loading…
May-01-25 10:46PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
01:11PM	Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:20AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:22AM	Alnylam: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Apr-30-25 08:02PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
05:15PM	MiMedx (MDXG) Q1 Earnings Match Estimates (Zacks)
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
Apr-29-25 04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
09:15AM	Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
08:00AM	Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Apr-24-25 10:01AM	Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline (Zacks)
Apr-17-25 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results (Business Wire)
Apr-14-25 02:03PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +5.08%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks) -6.98%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 02:08PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-04-25 08:04PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -10.08%
04:54PM	Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor (Zacks)
Apr-02-25 06:20AM	Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar? (Zacks)
Apr-01-25 09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks) -5.28%
08:00AM	Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-29-25 01:00PM	Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 (Business Wire)
Mar-28-25 04:44PM	FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:30AM	Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks)
Mar-25-25 07:28AM	Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts (SeekingAlpha)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-22-25 09:40AM	Alnylam price target raised to $338 from $300 at Scotiabank (TipRanks)
Mar-21-25 07:13PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +11.75%
05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
12:46PM	Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy (Zacks)
11:30AM	BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
07:37AM	Alnylam prices heart drug at premium to rivals (BioPharma Dive)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
05:54PM	Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) (Business Wire)
01:57PM	Alnylam drug gets long-awaited FDA approval in deadly heart disease (BioPharma Dive)
Mar-11-25 08:00AM	Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum (Business Wire)
Mar-05-25 07:00AM	Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day (Business Wire)
Feb-24-25 07:11PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:59PM	Alnylam Pharmaceuticals (ALNY): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey)
Feb-14-25 04:35PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
02:10AM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-13-25 11:26PM	Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:30AM	Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:18AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-10-25 09:16AM	Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-06-25 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-23-25 09:50AM	Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock (Zacks)
Jan-21-25 07:20PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.60%
09:40AM	Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? (Zacks)
Jan-12-25 04:00PM	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals (Business Wire)
Jan-06-25 08:00AM	Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-25-24 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-23-24 10:09AM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? (Insider Monkey)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Option Exercise	118.46	31,640	3,748,149	80,588	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Option Exercise	118.73	19,297	2,291,057	68,245	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Sale	304.39	31,640	9,630,902	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Sale	306.00	19,297	5,904,882	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Officer	Jun 02 '25	Proposed Sale	303.10	19,297	5,848,824		Jun 02 04:08 PM
Greenstreet Yvonne	Officer	May 30 '25	Proposed Sale	304.39	31,640	9,630,902		May 30 04:18 PM
SHARP PHILLIP A	Director	May 30 '25	Proposed Sale	300.00	11,250	3,375,000		May 30 04:10 PM
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Aug 29 '24	Buy	286.00	32	9,152	32	May 12 04:05 PM
Reitan Colleen F	Director	Oct 17 '24	Buy	302.67	4	1,211	36	May 12 04:05 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Option Exercise	42.22	5,445	229,888	25,666	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Sale	300.00	5,445	1,633,500	20,221	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 21 '25	Sale	285.00	4,321	1,231,485	20,221	Mar 25 04:10 PM
PYOTT DAVID E I	Director	Mar 24 '25	Option Exercise	88.95	7,440	661,788	7,576	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Sale	299.00	7,440	2,224,560	136	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Proposed Sale	299.00	7,440	2,224,560		Mar 24 04:13 PM
Garg Pushkal	Officer	Mar 24 '25	Proposed Sale	300.00	5,445	1,633,500		Mar 24 04:06 PM
Garg Pushkal	Officer	Mar 21 '25	Proposed Sale	285.00	4,321	1,231,485		Mar 21 04:03 PM
SCHULMAN AMY W	Director	Mar 13 '25	Option Exercise	131.21	2,750	360,828	11,186	Mar 14 04:16 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 14 '25	Sale	255.17	1,213	309,527	81,526	Feb 18 04:49 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 14 '25	Sale	255.17	967	246,750	32,786	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 18 '25	Sale	251.56	1,440	362,243	12,881	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 14 '25	Sale	255.21	663	169,204	14,321	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 14 '25	Sale	255.17	1,561	398,325	13,537	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 18 '25	Sale	251.67	1,548	389,579	11,989	Feb 18 04:47 PM
Garg Pushkal	Officer	Feb 18 '25	Proposed Sale	256.95	1,548	397,759		Feb 18 04:14 PM
Fitzgerald Kevin Joseph	Officer	Feb 18 '25	Proposed Sale	256.95	1,440	370,008		Feb 18 04:13 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Option Exercise	88.95	48,876	4,347,520	64,581	Jan 29 04:03 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Sale	285.00	52,592	14,988,720	11,989	Jan 29 04:03 PM
Garg Pushkal	Officer	Jan 27 '25	Proposed Sale	285.00	52,592	14,988,720		Jan 27 04:01 PM
SHARP PHILLIP A	Director	Jan 23 '25	Option Exercise	131.21	11,250	1,476,112	11,250	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Sale	275.00	11,250	3,093,750	0	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Proposed Sale	275.00	11,250	3,093,750		Jan 23 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Dec 12 '24	Sale	251.00	1,752	439,760	15,705	Dec 13 04:13 PM
Garg Pushkal	Officer	Dec 12 '24	Proposed Sale	255.02	1,752	446,795		Dec 12 04:05 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '24	Sale	250.98	5,219	1,309,853	78,880	Nov 27 05:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Nov 26 '24	Sale	250.98	1,682	422,144	17,457	Nov 27 05:22 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Nov 26 '24	Sale	250.98	1,682	422,144	30,644	Nov 27 05:21 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Nov 26 '24	Sale	250.98	1,469	368,686	13,191	Nov 27 05:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 27 '24	Sale	252.29	1,531	386,261	12,881	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 26 '24	Sale	250.98	1,469	368,686	14,412	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	Officer	Nov 27 '24	Proposed Sale	253.98	1,531	388,843		Nov 27 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Option Exercise	85.00	15,000	1,275,000	88,441	Aug 22 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Sale	280.00	15,000	4,200,000	73,441	Aug 22 08:01 PM
Greenstreet Yvonne	Officer	Aug 20 '24	Proposed Sale	280.00	15,000	4,200,000		Aug 20 05:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Option Exercise	89.09	20,725	1,846,429	34,906	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Sale	270.99	22,025	5,968,516	12,881	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	Officer	Aug 12 '24	Proposed Sale	269.52	22,025	5,936,178		Aug 12 04:07 PM
Ausiello Dennis A	Director	Aug 06 '24	Option Exercise	119.68	20,250	2,423,452	20,386	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Sale	262.00	20,250	5,305,586	136	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Proposed Sale	266.66	20,250	5,399,865		Aug 06 04:07 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Option Exercise	85.00	15,148	1,287,580	88,589	Aug 02 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Sale	270.00	15,148	4,089,960	73,441	Aug 02 08:01 PM
Greenstreet Yvonne	Officer	Aug 01 '24	Proposed Sale	270.00	15,148	4,089,960		Aug 01 04:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience